Hedera Dx is a biotechnology company focused on advancing liquid biopsy technology for oncology. Their solution enables hospital laboratories to conduct in-house, CE-IVDR compliant liquid biopsies to profile circulating tumor DNA (ctDNA) from a simple blood draw. This approach seeks to streamline tumor profiling and cancer treatment monitoring, expanding therapy options for patients, particularly those who cannot undergo traditional tissue biopsies. Their work involves a pan-cancer targeted assay and software that simplifies integration into existing lab settings, providing actionable information for personalized patient treatment plans. Hedera Dx aims to make liquid biopsies globally accessible and continues to develop clinical trials and evidence to support real-world utility and validation in various cancers.